Is There Any Difference in the In Situ Immune Response in Active Localized Cutaneous Leishmaniasis That Respond Well or Poorly to Meglumine Antimoniate Treatment or Spontaneously Heal?
نویسندگان
چکیده
Localized cutaneous leishmaniasis caused by Leishmania braziliensis can either respond well or poorly to the treatment heal spontaneously; It seems be dependent on parasite and/or host factors, but mechanisms are not fully understood. We evaluated in situ immune response eighty-two active lesions from fifty-eight patients prior classified as early spontaneous regression (SRL-n = 14); responders (GRL-n 20); and non-responders (before first treatment/relapse, PRL1/PRL2-n 24 each). Immunohistochemistry was used identify cell/functional markers which were correlated with clinical characteristics. PRL showed significant differences lesion number/size, evolution, positive parasitological examinations when compared other groups. SRL presented a more efficient than GRL PRL, higher IFN-γ/NOS2 lower percentage of macrophages, neutrophils, NK, B cells, Ki-67+ cells. Compared SRL, had fewer CD4+ Tcells CD163+ macrophages. PRL1 CD68+ macrophages cells less IFN-γ GRL. present profile, could explain poor response, while balanced profile for healing. Altogether, these evaluations suggest differentiated organization inflammatory process different tegumentary evolution.
منابع مشابه
omparative study of oral azithromycin and systemic meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis
Background and aim: Complications and resistance to pentavalent antimonial agents in cutaneous leishmaniasis, exhibit the need for effective alternative drugs. The aim of this study was to compare the efficacy of oral azithromycin with systemic meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. Materials and Methods: Forty-seven patients with cutaneous leishmaniasis...
متن کاملClinical and Parasitological Features of Patients with American Cutaneous Leishmaniasis that Did Not Respond to Treatment with Meglumine Antimoniate
BACKGROUND American cutaneous leishmaniasis (ACL) is a complicated disease producing about 67.000 new cases per year. The severity of the disease depends on the parasite species; however in the vast majority of cases species confirmation is not feasible. WHO suggestion for ACL produced by Leishmania braziliensis, as first line treatment, are pentavalent antimonial derivatives (Glucantime or Sod...
متن کاملThe effect of combination therapy with systemic Meglumine Antimoniate (Glucantime) and Pentoxifylline in the treatment of cutaneous Leishmaniasis
.
متن کاملEfficacy of topical 5% imiquimod with cryotherapy versus intralesional meglumine antimoniate in the treatment of anthroponotic cutaneous leishmaniasis
Background: Cutaneous leishmaniasis (CL) is a major world problem. Several types of treatment regimens have been suggested. Imiquimod demonstrated a leishmanicidal activity by increasing local cytokine production. The aim of this study was to determine the efficacy of topical 5% imiquimod with cryotherapy vs. intralesional meglumine antimoniate (MA) in treatment of anthroponotic (dry type) CL. ...
متن کاملA comparison between intralesional hypertonic Sodium Chloride solution and Meglumine Antimoniate (Glucantime) injections in the treatment of cutaneous Leishmaniasis
Background and objective: Different local and systemic modalities are suggested in the treatment of cutaneous leishmaniasis, but the pentavalent antimony compounds are still considered as the first line of treatment. Regarding to increase in clinical drug resistance and adverse effects, efforts to find a more effective and safer drug is continuing. The objective of this study was to compa...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Microorganisms
سال: 2023
ISSN: ['2076-2607']
DOI: https://doi.org/10.3390/microorganisms11071631